Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,612.40
(
0.11%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
101.17
(
0.00%
)
Bitcoin
77,281.37
(
0.35%
)
News Focus
News Focus
Post# of 257627
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123010
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 216884

Wednesday, 02/07/2018 4:28:13 PM

Wednesday, February 07, 2018 4:28:13 PM

Post# of 257627
ENTA FY1Q18 results:

http://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-12

Revenue was $38.1M, of which $23.1M came from royalties and $15.0M from a milestone payment for Mavyret approval in Japan. GAAP EPS was $0.59.

Cash at 12/31/17 was $297.5M.

Gross operating expenses were $23.7M—well below the FY2018 quarterly guidance range of $30.5-34.5M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today